8-K: MetaVia's DA-1726 Shows Strong Phase 1 Obesity Results

MetaVia Inc. announced positive statistically significant results from its Phase 1 clinical trial of DA-1726 for obesity, demonstrating robust weight loss, glycemic response, and hepatic benefits.

Summary

• DA-1726, a novel dual oxyntomodulin (OXM) analog agonist (GLP1R and GCGR), is being developed for the treatment of obesity.
• The Phase 1 clinical trial's 8-week (extended from four weeks) non-titrated 48 mg, multiple ascending dose (MAD) cohort yielded positive statistically significant results.
• Patients achieved an average weight reduction of 6.1% (14.6 lbs) by Day 26 (p=0.003) and 9.1% (21.2 lbs) by Day 54.
• Statistically significant reductions in waist circumference were observed: 5.8 cm (2.3 inches) by Day 26 (p=0.006) and 9.8 cm (3.8 inches) by Day 54 (p=0.022).
• A strong glycemic response was noted with a 12.3 mg/dL reduction in fasted glucose by Day 54, from a baseline of 105.3 mg/dL.
• Vibration-controlled transient elastography (VCTE) indicated a 23.7% reduction in liver stiffness from a baseline of 5.9 kPa by Day 54, suggesting a significant direct hepatic effect.
• The trial demonstrated a favorable safety and tolerability profile, with no treatment-related discontinuations and gastrointestinal events reported as mild to moderate in severity.
• Early HbA1c benefits were observed in a prediabetic subject, with a drop from 6.0% to 5.5% by Day 54.

Sentiment

Score: 9

Explanation: The filing reports highly positive, statistically significant results across multiple key metrics (weight loss, waist circumference, glucose control, liver stiffness) for a drug in a high-demand therapeutic area, with a favorable safety profile and strong competitive positioning against existing treatments. This indicates strong progress and potential for the company.

Positives

• Statistically significant average weight reduction of 9.1% (21.2 lbs) by Day 54.
• Statistically significant waist circumference reduction of 9.8 cm (3.8 inches) by Day 54 (p=0.022).
• Strong glycemic response with a 12.3 mg/dL fasted glucose reduction by Day 54.
• Significant direct hepatic activity demonstrated by a 23.7% reduction in liver stiffness (VCTE) by Day 54.
• Favorable safety and tolerability profile with no treatment-related discontinuations.
• Gastrointestinal events were mild to moderate in severity.
• Potential for deeper visceral fat loss due to the glucagon component of DA-1726.
• Observed early HbA1c benefits in a prediabetic subject, dropping from 6.0% to 5.5% by Day 54.
• DA-1726 has the potential to be the most effective GLP-1/glucagon dual agonist in development that has demonstrated glucose lowering without elevations.
• VCTE reduction is recognized by the FDA as a biomarker in MASH development, highlighting the drug's hepatic potential.

Risks

• Ability to execute on commercial strategy.
• Sufficiency of existing cash on hand to fund operations.
• Timeline for regulatory submissions.
• Ability to obtain regulatory approval through the development steps of current and future product candidates.
• Cooperation of contract manufacturers, clinical study partners, and others involved in product development.
• Potential negative interactions between product candidates and any other products with which they are combined for treatment.
• Ability to initiate and complete clinical trials on a timely basis.
• Ability to recruit subjects for clinical trials.
• Whether clinical trial results are consistent with the results of pre-clinical and previous clinical trials.
• Impact of costs related to license agreements, known and unknown, including costs of any litigation or regulatory actions.
• Effects of changes in applicable laws or regulations.
• Effects of changes to stock price on the terms of license agreements and any future fundraising.

Future Outlook

MetaVia plans to conduct 16-week titration studies for DA-1726, including a single-step titration to 48 mg and a two-step regimen to 64 mg, with results anticipated in the fourth quarter of 2026. The company expresses confidence in DA-1726's tolerability and expects its titration schedules to compare favorably to the slower, more restrictive schedules of current GLP-1 drugs, viewing this as a key competitive advantage. The company aims to unlock further value as DA-1726 advances toward later-stage development.

Management Comments

• "Extending DA-1726 administration to a full eight weeks at the non-titrated 48 mg dose has provided us with extremely encouraging insights."
• "We believe the statistically significant waist reductions reflect the glucagon component of DA-1726, which may contribute to deeper visceral fat loss than GLP-1 agonists alone."
• "Combined with a favorable tolerability profile with no treatment-related discontinuations, these results highlight DA-1726s differentiated potential to be a best-in-class treatment option."
• "DA-1726 has the potential to be the most effective GLP-1/glucagon dual agonist in development that has demonstrated glucose lowering without elevations, which may offer both clinical and reimbursement advantages."
• "Taken together, the data reinforce our view that DA-1726 has best-in-class potential, delivering a compelling balance of weight loss, metabolic improvement, direct hepatic benefit, and tolerability as we advance toward later-stage development."
• "Our planned 16-week titration studiesto 48 mg in a single step and to 64 mg using a two-step regimenreflect our confidence in DA-1726s tolerability and our expectation that it will compare favorably to the slower, more restrictive titration schedules required by todays GLP-1 drugs. We believe this represents a key competitive advantage."

Industry Context

The announcement positions DA-1726 as a promising candidate in the competitive and rapidly expanding market for cardiometabolic diseases, particularly obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Its dual GLP1R/GCGR agonism offers a differentiated mechanism that may lead to superior outcomes, such as deeper visceral fat loss and glucose lowering without elevations, addressing a large patient population where 70-80% of obese individuals also have diabetes or prediabetes. The demonstrated reduction in liver stiffness (VCTE) is particularly relevant for MASH development, an area with significant unmet medical needs, potentially offering a comprehensive solution for patients with co-morbidities.

Comparison to Industry Standards

• DA-1726 is positioned to offer superior body weight loss compared to selective GLP-1R agonists due to its dual GLP1R/GCGR agonism.
• In pre-clinical mouse models, DA-1726 resulted in improved weight loss compared to semaglutide (Wegovy).
• In pre-clinical mouse models, DA-1726 elicited similar weight reduction while consuming more food compared to tirzepatide (Zepbound) and survodutide.
• DA-1726 demonstrated improved lipid-lowering effects compared to survodutide in pre-clinical mouse models.
• The planned 16-week titration studies aim for faster, less restrictive schedules compared to current GLP-1 drugs, which is highlighted as a key competitive advantage.

Stakeholder Impact

• Shareholders: Positive results could lead to increased investor confidence and potential share price appreciation, especially given the 'best-in-class' potential and competitive advantages.
• Patients (Obesity/Prediabetes/MASH): Offers a promising new treatment option with a differentiated mechanism, potentially leading to better outcomes, including deeper visceral fat loss and hepatic benefits, with a favorable tolerability profile.
• Healthcare Providers: Provides a new therapeutic tool with potential advantages over existing treatments, particularly concerning titration schedules and direct hepatic effects.
• Competitors: Poses a competitive threat to companies developing GLP-1 agonists and other obesity/MASH treatments, especially given the claims of 'best-in-class potential.'

Next Steps

• Conduct planned 16-week titration studies (to 48 mg in a single step and to 64 mg using a two-step regimen).
• Expect results from titration studies in the fourth quarter of 2026.
• Advance DA-1726 toward later-stage development.

Key Dates

Recommendation

The reported Phase 1 results for DA-1726 are exceptionally strong and statistically significant across multiple critical endpoints, including robust weight loss, significant waist circumference reduction, strong glycemic control, and meaningful direct hepatic benefits. The favorable safety and tolerability profile, with no treatment-related discontinuations, is a key differentiator. Management's confidence in a competitive titration schedule and the drug's potential to be 'best-in-class' in a massive and growing market (obesity, prediabetes, MASH) suggests substantial future value creation. The preclinical comparisons to established drugs like semaglutide and tirzepatide, showing superior or comparable efficacy with additional benefits, further bolster its potential. This filing indicates a significant de-risking event for the asset and positions MetaVia for strong future growth, making it a compelling 'strong buy' for investors.

Keywords

Obesity, DA-1726, GLP-1, Glucagon, Dual Agonist, Weight Loss, Liver Stiffness, Fasted Glucose, Cardiometabolic, Biotechnology, MASH, Phase 1 Clinical Trial, Oxyntomodulin